STAT+: The biotech scorecard for the second quarter: 23 stock-moving events to watch

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the second quarter:

Abivax: Maintenance outcomes from the Phase 3 ABTECT study of obefazimod in ulcerative colitis.

Allogene Therapeutics: Interim analysis of the ALPHA3 study of cema-cel as a frontline consolidation treatment for B-cell lymphoma. A preview can be read here.

Continue to STAT+ to read the full story…